Magnetic resonance imaging (MRI) of gadolinium (Gd)-based contrast agents plays a central role in managing the treatment of intracranial tumors. These images are involved in diagnosis, surgical planning, surgical navigation, and postoperative assessment of extent of resection. Replicating the information from Gd-MRI in the visual surgical field using fluorescent agents that behave similar to gadolinium in vivo would represent a major advance for surgical intervention of these tumors, and could provide robust compensation information to update pre-operative MRI images during surgery. In this paper, we examine the uptake of a Gd-based contrast agent in orthotopic tumor models and compare this behavior to two fluorescein-based contrast agents; specifically, clinical-grade sodium fluorescein (NaFl) and a 900 Da pegylated form of fluorescein. We show that the pegylated form of fluorescein is a more promising Gd-analog candidate.
INTRODUCTION
Surgical resection is a primary treatment modality for intracranial tumors, and there is mounting evidence that maximizing extent of resection during cytoreductive surgery improves outcomes. [1] [2] [3] [4] A central role in the management of these lesions is MRI imaging of gadolinium-based contrast agents, which is involved in diagnosis, surgical planning, intra-surgical guidance and assessment of extent of resection after surgery. Tumor-to-normal contrast, which can be quite high, is generally understood to arise from leakage and retention of the contrast agent in tumor regions which have compromised the blood brain barrier (BBB). During surgery, the MRI images with segmented Gd-defined tumor regions are coregistered to the patient and provide direct guidance and navigation for the surgeon. However, the concordance between these imaged volumes and the tissue is affected by patient positioning and other changes caused by the intervention itself. This brain shift phenomenon is a major challenge for surgical navigation and has been a focus of widespread research efforts to develop compensation techniques. These include intra-surgical ultrasound or stereovision coupled to deformation models to update the pre-operative MRI, and fluorescence guided surgery to guide tumor resection in the visual field. [5] [6] [7] [8] [9] Combining these approaches may provide a particularly effective solution. Specifically, a fluorescent contrast agent that behaves similar to Gd-MRI could provide an ideal sparse data set for compensatory pre-operative MRI image updating.
Sodium fluorescein (NaFl) is a fluorescent agent approved for clinical use in retinal angiography and has been investigated for decades as a tumor marker for glioma during surgery. [10] [11] [12] [13] [14] However, the observed behavior of this agent in vivo has been mixed, often showing significant uptake in normal tissue. In a recent study, we reported on a comprehensive examination of the kinetics of NaFl in blood, normal brain, and tumor.
Herein, we investigate Gd uptake in orthotopic glioma models over time and discuss the potential for NaFl and/or the pegylated form to mimic the kinetics of Gd-based contrast agents, potentially serving as an optical analog to Gd-MRI for surgical guidance.
MATERIALS AND METHODS
All animal procedures were approved and conducted in accordance with policies by Dartmouth's IACUC. The orthotopic tumor xenograft model consisted of U251 tumor cells implanted intracranially in athymic nude mice. This is a well-known glioma line that highlights on MRI due to the breakdown of the BBB in the tumor. After implantation of 10 6 cells, the tumors grew for 3-5 weeks, during which the tumors were monitored using MRI. Once tumors were 3-4 mm across, they were put on study.
For MRI imaging, animals were positioned in a customized rodent coil compatible with a Philips Achieva 3T clinical scanner 16 . High resolution T1-and T2-weghted images followed by one set of fast T1-weighted images (4 slices) were acquired prior to Gd administration. Dynamic imaging (fast T1W images) began immediately after the administration of gadobutrol in the tail vain and was run for about 70 minutes after administration at a rate of 89 seconds per frame.
Animals in the fluorescence imaging group were administered NaFl or Pegylated fluorescein in the tail vein and then sacrificed at the pre-determined time point after administration, as describe previously 15 . Brains ware harvested, gross sectioned, and imaged with a Typhoon flatbed scanner. Finally, tissue was processed for H&E analysis to confirm the presence of tumor. Figure 1 shows one T1W slice at several time points after Gd administration from the fast, low resolution dynamic scan sequence. The left column shows the pre-injection image and the remaining images are post-contrast images after subtraction of the pre-contrast images. Notable in almost all images is the strong tumor contrast compared to normal brain (over 10:1 in some cases).
RESULTS AND DISCUSSION
An optical agent that provided similar uptake to gadolinium would be useful for surgical guidance, and could even serve as sparse data for brain shift compensation during surgery. However, our results published previously 15 show that NaFl would be a poor choice given the propensity of the agent to leak into normal brain tissue. Our results showed that tumor to normal contrast was severely limited by this effect. Examples of the NaFl images from representative mice are presented in Fig. 2 . 30 min. 60 min.
As observed in the images, and previously reported, the presence of NaFl in the normal brain limits the achievable contrast, which is nowhere near as high as observed in the Gd-MRI images (maximum around 2:1). To address this, we proposed the use of fluorescein modified with a short PEG molecule. 15 This molecule was chosen to have a similar size to gadolinium-based chelates used in MRI. Example images of pegylated fluorescein in brain sections are shown in Fig. 3 .
These images show much higher tumor-to-background contrast more in line with what was observed in the Gd-MRI images.
CONCLUSION
Considering the central role of Gd-MRI in diagnosing, treating, and monitoring intracranial tumors, the introduction of an optical analog to gadolinium-based MRI contrast agents would be a major development for guiding the resection of these lesions. Until recently, an obvious candidate was NaFl, given its long historical use in humans and the ongoing interest in its use for surgical guidance. However, we previously showed that NaFl is a poor candidate for this application due to its behavior in normal brain tissue, which does not correspond to gadobutrol, as shown herein. A pegylated form of fluorescein which does not cross the normal blood brain barrier shows promise as an alternative candidate. Tumor contrast using this form was higher than for NaFl alone, and the observed uptake patterns were closer to those of Gd-MRI. Further studies using co-registered MRI and cryomacrotome fluorescence imaging will be completed to evaluate this and other candidates.
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